CN116096757B - 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途 - Google Patents

抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途 Download PDF

Info

Publication number
CN116096757B
CN116096757B CN202180061976.8A CN202180061976A CN116096757B CN 116096757 B CN116096757 B CN 116096757B CN 202180061976 A CN202180061976 A CN 202180061976A CN 116096757 B CN116096757 B CN 116096757B
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
variable region
antibody variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180061976.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN116096757A (zh
Inventor
井川佑理
大仓有生
沟吕木晓彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to CN202311818773.6A priority Critical patent/CN117801115A/zh
Priority to CN202311813323.8A priority patent/CN117801114A/zh
Publication of CN116096757A publication Critical patent/CN116096757A/zh
Application granted granted Critical
Publication of CN116096757B publication Critical patent/CN116096757B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180061976.8A 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途 Active CN116096757B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311818773.6A CN117801115A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
CN202311813323.8A CN117801114A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-157873 2020-09-18
JP2020157873 2020-09-18
PCT/JP2021/034240 WO2022059766A1 (en) 2020-09-18 2021-09-17 Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311813323.8A Division CN117801114A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
CN202311818773.6A Division CN117801115A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途

Publications (2)

Publication Number Publication Date
CN116096757A CN116096757A (zh) 2023-05-09
CN116096757B true CN116096757B (zh) 2024-01-12

Family

ID=80739984

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202311813323.8A Pending CN117801114A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
CN202180061976.8A Active CN116096757B (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
CN202311818773.6A Pending CN117801115A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202311813323.8A Pending CN117801114A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311818773.6A Pending CN117801115A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途

Country Status (16)

Country Link
US (2) US11739153B2 (enExample)
EP (1) EP4214236A4 (enExample)
JP (2) JP7147030B2 (enExample)
KR (2) KR20230116942A (enExample)
CN (3) CN117801114A (enExample)
AR (1) AR123537A1 (enExample)
AU (1) AU2021343008B2 (enExample)
CA (1) CA3192661A1 (enExample)
CL (1) CL2023000765A1 (enExample)
CO (1) CO2023003681A2 (enExample)
CR (1) CR20230166A (enExample)
IL (1) IL301326A (enExample)
MX (1) MX2023002191A (enExample)
PE (1) PE20231208A1 (enExample)
TW (2) TW202402804A (enExample)
WO (1) WO2022059766A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020204054A1 (en) * 2019-04-01 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
TW202402804A (zh) 2020-09-18 2024-01-16 日商中外製藥股份有限公司 抗hla-dq2.5抗體及其用於治療乳糜瀉的用途
US20240400693A1 (en) * 2021-10-08 2024-12-05 Chugai Seiyaku Kabushiki Kaisha Drug formulation of anti-hla-dq2.5 antibody
MX2024004117A (es) * 2021-10-08 2024-04-19 Chugai Pharmaceutical Co Ltd Metodo para preparar formulacion de jeringa precargada.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104011207A (zh) * 2011-10-31 2014-08-27 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
CN111225925A (zh) * 2017-10-03 2020-06-02 中外制药株式会社 抗hla-dq2.5抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
MXPA03009313A (es) 2001-04-12 2004-11-12 Academish Ziekenhuis Leiden Metodos y medios para uso de receptores de celulas t restringidos por hla-dq y peptidos derivados de prolamina unidos a hla-dq.
CN102202643A (zh) 2008-02-07 2011-09-28 安姆根有限公司 稳定化的蛋白组合物
AU2013204429B9 (en) 2008-11-30 2017-01-05 Immusant, Inc. Compositions and methods for treatment of celiac disease
US8673300B2 (en) 2009-06-04 2014-03-18 The Regents Of The University Of Colorado, A Body Corporate Therapeutic compositions and methods for the prevention of autoimmune diseases
RU2013106217A (ru) 2010-08-05 2014-09-10 Ф. Хоффманн-Ля Рош Аг Гибридный белок из антитела против мнс и противовирусного цитокина
WO2016202805A2 (en) 2015-06-15 2016-12-22 Consejo Superior De Investigaciones Científicas (Csic) Targeting of prolamin by rnai in bread wheat
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US20200040085A1 (en) * 2017-02-27 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease
GB201802338D0 (en) * 2018-02-13 2018-03-28 Univ Oslo Antigen binding proteins
WO2020204054A1 (en) * 2019-04-01 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
TW202402804A (zh) 2020-09-18 2024-01-16 日商中外製藥股份有限公司 抗hla-dq2.5抗體及其用於治療乳糜瀉的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104011207A (zh) * 2011-10-31 2014-08-27 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
CN111225925A (zh) * 2017-10-03 2020-06-02 中外制药株式会社 抗hla-dq2.5抗体

Also Published As

Publication number Publication date
IL301326A (en) 2023-05-01
TWI820484B (zh) 2023-11-01
JP7147030B2 (ja) 2022-10-04
MX2023002191A (es) 2023-03-03
WO2022059766A1 (en) 2022-03-24
CN116096757A (zh) 2023-05-09
AU2021343008A1 (en) 2023-06-01
KR20220153469A (ko) 2022-11-18
KR102559128B1 (ko) 2023-07-24
TW202229345A (zh) 2022-08-01
US20230357408A1 (en) 2023-11-09
AR123537A1 (es) 2022-12-14
PE20231208A1 (es) 2023-08-17
CN117801114A (zh) 2024-04-02
KR20230116942A (ko) 2023-08-04
AU2021343008A9 (en) 2024-10-10
CA3192661A1 (en) 2022-03-24
AU2021343008B2 (en) 2025-11-13
US20220089743A1 (en) 2022-03-24
CN117801115A (zh) 2024-04-02
CL2023000765A1 (es) 2023-11-03
JP2022051553A (ja) 2022-03-31
EP4214236A1 (en) 2023-07-26
EP4214236A4 (en) 2024-10-30
US11739153B2 (en) 2023-08-29
CR20230166A (es) 2023-05-31
TW202402804A (zh) 2024-01-16
JP2022172276A (ja) 2022-11-15
CO2023003681A2 (es) 2023-04-05

Similar Documents

Publication Publication Date Title
JP7592050B2 (ja) 抗ｈｌａ－ｇ抗体とその使用
EP3215532B1 (en) Anti-tim3 antibodies and methods of use
JP7141336B2 (ja) 抗ミオスタチン抗体および使用方法
CN116096757B (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
CN107428823B (zh) 两种以上抗-c5抗体的组合与使用方法
CN103890006A (zh) 抗mcsp抗体
JP2025038092A (ja) 抗ｈｌａ－ｄｑ２．５抗体
CN106459197A (zh) 结合HER1 β‑发夹的HER1抗原结合蛋白
TW202333781A (zh) 抗ｈｌａ－ｄｑ２﹒５抗體製劑
HK40084713A (en) Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease
KR102614250B1 (ko) 항hla-dq2.5 항체의 제제
HK40084713B (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
CN118369115A (zh) 抗hla-dq2.5抗体的药物制剂
HK40062978A (en) Anti-hla-dq2.5 antibody
CN104936987A (zh) 抗mcsp抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40084713

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant